SCHEMBL29893306

SCHEMBL29893306

Nc1ccc2c(c1)ncc1cccn12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.62
KDM4E B2RXH2 4/20 0.62
HSD17B10 Q99714 2/20 0.62
GAA P10253 2/20 0.62
GLA P06280 1/20 0.62
HPGD P15428 1/20 0.62
FGFR1 P11362 1/20 0.44
MAPT P10636 4/20 0.41
RAD51 Q06609 8/20 0.40
TDP1 Q9NUW8 2/20 0.38
NPC1 O15118 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 1/20 0.38
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
CHEK1 O14757 1/20 0.38
LIMK1 P53667 1/20 0.38
MAPK14 Q16539 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30932617 0.80 KDM4E (0.62) ALDH1A1KDM4EHSD17B10GAAGLA
SCHEMBL29229018 0.80 KDM4E (0.62) ALDH1A1KDM4EHSD17B10GAAGLA
SCHEMBL30657604 0.80 KDM4E (0.62) ALDH1A1KDM4EHSD17B10GAAGLA
SCHEMBL31612371 0.80 ALDH1A1 (0.62) ALDH1A1KDM4EHSD17B10GAAGLA
SCHEMBL29127007 0.80 KDM4E (0.62) ALDH1A1KDM4EHSD17B10GAAGLA
SCHEMBL29126970 0.80 KDM4E (0.67) ALDH1A1KDM4EHSD17B10GAAGLA
SCHEMBL29229124 0.80 ALDH1A1 (0.62) ALDH1A1KDM4EHSD17B10GAAGLA
SCHEMBL31612336 0.80 ALDH1A1 (0.62) ALDH1A1KDM4EHSD17B10GAAGLA
SCHEMBL29126966 0.78 ALDH1A1 (0.59) ALDH1A1KDM4EHSD17B10GAAGLA
SCHEMBL30657609 0.78 ALDH1A1 (0.59) ALDH1A1KDM4EHSD17B10GAAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313308-A1 TEAD INHIBITORS AND USES THEREOF Cedilla Therapeutics, Inc. (US) 2024-02-07 EP disclosed
US-20230098872-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. 2023-03-30 US disclosed
WO-2022204452-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. (US) 2022-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230098872-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 ALDH1A1 1319/4885KDM4E 1730/4885HSD17B10 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.